Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development
MAJ Il y a 4 ans
A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)
To evaluate safety and efficacy of FF/GW642444 50mcg/25mcg QD and FF/GW642444 100mcg/25mcg QD and FF/GW642444 200mcg/25mcg QD versus GW642444 25mcg QD on the annual rate of moderate and severe exacerb...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
Study to evaluate immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ Inactivated Polio Vaccine (Poliorix) in healthy Chinese toddlers
To assess the immunological response to a booster dose of GSK Biologicals’ IPV in terms of poliovirus type 1, 2 and 3 antibodies, one month after the booster dose in subjects primed with three doses o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase IV, open, non-randomised, multicentre study to assess the reactogenicity and immunogenicity of a booster dose of GSK Biologicals’ combined reduced-antigen-content diphtheria-tetanus, acellular pertussis and inactivated poliovirus vaccine dTpa-IPV (Boostrix-Polio) when administered in healthy subjects aged 9-13 years, 5 years after previous booster vaccination with dTpa-IPV in the study 711866/001 (dTpa-IPV-001)
To assess the incidence of grade 3 local reactions occurring during the 4-day (Day 0 - Day 3) follow-up period after administration of a booster dose of dTpa-IPV vaccine in healthy children and adoles...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GSK573719 with tiotropium over 24 weeks in subjects with COPD
The primary objective is to compare the efficacy of two doses of GSK573719/GW642444 Inhalation Powder (125mcg/25mcg and 62.5/25mcg once-daily) with GSK573719 (125mcg once daily) and with tiotropium (1...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A study to evaluate reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated liquid human rotavirus (HRV) vaccine 444563, in healthy infants
To assess the reactogenicity of GSK Biologicals’ liquid HRV vaccine when compared to placebo in terms of grade “3” solicited adverse events (AEs).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development
MAJ Il y a 4 ans
Clinical Evaluation of lamotrigine in Epilepsy
To provide confidence in the safety of LTG, as measured by the incidence of rash (including SJS and any other serious drug eruption) in the first 8 weeks of treatment, in Japanese patients with epilep...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
GlaxoSmithKline (The Netherlands)
MAJ Il y a 4 ans
A multicentre, parallel group, randomised, double blind study to investigate the efficacy of fluticasone 100 mcg metered dose inhaler (MDI) twice a day (bd) versus placebo MDI bd both via Babyhaler® spacer in 1 to 5 year old children with asthma or asthma-like symptoms during a 6 month study period
Not provided at time of registration
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
Development of read-outs in healthy, hepatitis B virus naive adults vaccinated with the hepatitis B surface antigen (HBsAg) in combination with a GlaxoSmithKline (GSK) Biologicals’ Adjuvant System
To detect and measure soluble mediators from the early immune response in plasma.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline, S.A
MAJ Il y a 4 ans
A double-blind, randomized, placebo-controlled, multi-centre, dose-ranging, parallel group, phase II study to assess efficacy, safety/tolerability, and pharmacokinetics of a thrombopoietin receptor agonist, SB-497115-GR, when administered as 30, 50, and 75 mg once daily for 12 weeks in subjects with chronic hepatitis C–related thrombocytopenia who are potential candidates for antiviral treatment with pegylated interferon and ribavirin
1. To evaluate the effects of SB-497115-GR on platelet counts when administered once daily for 4 weeks (Part 1) to subjects with chronic hepatitis C-related thrombocytopenia, prior to receiving antiv...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline (Netherlands)
MAJ Il y a 4 ans
The effect of ondansetron, a 5-Ht3 receptor antagonist, on fatigue severity and functional impairment in Chronic Fatigue Syndrome patients
Not provided at time of registration
Pays
Netherlands
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant